RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness and aims to restore vision and transform the lives of patients worldwide.
Some insights
RhyGaze is advancing innovative approaches in genetic medicine for vision disorders, aiming to help protect and restore one of our most essential human senses in areas of high unmet medical need.
We are proud of the exceptional team at RhyGaze, whose deep experience, scientific rigor, and collaborative culture form the foundation of everything we do.
We admire companies and leaders who responsibly translate cutting-edge academic science into clinical development, balancing innovation with long-term thinking, transparency, and respect for patients and data quality.
We benefit from a strong, experienced team across gene therapy, ophthalmology, and regulatory affairs. While well positioned today, we value continuous learning and remain open to outstanding talent as we grow.
We are keen to stay connected with leading scientists, clinical investigators and especially patient advocacy groups, to ensure meaningful exchange and alignment as the field continues to evolve.